The Consolidated Research Group of Clinical and Molecular Microbiology integrates (1) Clinical Microbiology Staff and Residents of the Unit of Microbiology, University Hospital Reina Sofía, (2) Professors of the Department of Microbiology-Medical School, University of Cordoba, and (3) Other Researchers and Technicians with a contractual tie to our group.
The research interests of the group include:
- Antimicrobial resistance in bacteria of medical interest, with special attention to multiresistant gram-negative organisms.
- In vitro activity of new antimicrobial agents.
- Diagnostic methods in Clinical Microbiology.
In the area of major interest for the group (antimicrobial resistance), we consider both Enterobacteria (Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., etc.) and non-fermenters (Pseudomonas aeruginosa and other species, Actinetobacter baumannii and related species, Stenotrophomonas maltophilia, among others). Other studies are focused on methicillin-resistant Staphylococcus aureus and coryneform bacteria.
Our objectives include: (1) To study mechanisms causing low-level resistance: porin alterations, (over)production of efflux pumps, (2) To study mechanisms of resistance to specific antimicrobial groups, extended-sepctrum beta-lactamases, carbapenemases, plasmid-mediated quinolone resistance, type II topoisomerases, aminoglycoside-modifying enzymes, ARN 16S methyl-transferases)…, and (3) To characterize genes and mobile elements (plasmids, transposons, integrons, gene cassettes, etc.) involved in antimicrobial resistance.
We are also considering molecular epidemiology of multiresistant bacteria causing nosocomial infections, and the study of the relationship between antimicrobial resistance and virulence.
The achievements of our research include:
- Discovery of qnr genes, causing plasmid-mediated quinolone resistance. Detailed contribution of these genes to resistance and design of molecular methods for their detection.
- Demonstration of the importance of porins in of low-level resistance.
- Analysis of penicillin-binding proteins of multiresistant A. baumannii.
- Characterization of mechanisms of resistance to aminoglycosides in multiresistant enterobacteria, non-fermenters and corynebacteria.
- Demonstration of the importance of manganese contents in culture media when testing tigecycline.
- Collaboration in multiples clinical studies on treatment and prognosis of infections caused by multiresistant bacteria.
We contribute to the Programs “Resistance” and “Infections in Transplanted Patients” of the Spanish network for research on infectious diseases (REIPI, http://reipi.org/) supported by the Institute of Health Carlos III (ISCIII). This network has developed and is developing different multicenter studies on clinical and microbiological aspects of infections caused by resistant bacteria of clinical relevance.
Líneas de Investigación
- Beta-lactamases: Identification of genes coding for extended-espectrum beta-lactamases, AmpC-type beta-lactamases, carbapenemases and other beta-lactamases of clinical importance.
- Plasmid-mediated quinolone resistance: Qnr proteins and related mechanisms.
- Mechanisms of aminoglycoside resistance: Modifying enzymes and ARN 16S methyl-transferases.
- Low level resistance mechanisms, with interest in outer membrane proteins (particularly porins in enterobacterias and in Pseudomonas spp.) and efflux pumps.
- Heteroresistance to antimicrobial agents, focused on carbapenem and polymyxins.
- Genetic elements involved in horizontal gene transfer and its relevance for antimicrobial resistance.
- Bacterial targets: Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., other enterobacterias, Pseudomonas aeruginosa (and related species), Acinetobacter baumannii complex, Stenotrophomonas maltophilia, Staphylococcus aureus, coagulase-negative staphylococci, Corynebacterium and related genera.
- Development of new antimicrobial agents: chelocardin, new aminoglycosides.
- In vitro studies of new compounds, in collaboration with the pharmaceutical industry.
- Evaluation of Maldi-Tof for identification of microorgansims of clinical importance, including both bacteria and fungi.
- Use of molecular methods for identification of clinically important microorganisms.
- Evaluation of new commercial methods and assays for microbiological diagnosis.
- Evaluation of commercial and in-house methods for susceptibility testing of bacteria of clinical interest.
Networks
REIPI - Spanish Network for Research on Infectious Diseases
Andalusian Network For Clinical Research In Infectious Diseases. RIC-0537-2018.
Palabras Clave
- antimicrobial-resistance
- beta-lactamases
- aminoglycoside-modifying-enzymes
- methyl-transferases
- Qnr
- quinolones
- polymyxins
- carbapenems
- cephalosporins
- heteroresistance
- antibiogram
- susceptibility-testing
- molecular-typing
- enterobacteria
- pseudomonas
- acinetobacter
Información Adicional
Ongoing Projects
Heteroresistance and persistance in carbapenem-resistant Klebsiella pneumoniae. PI: Luis Martínez-Martínez. Funding agency: National Institute of Health Carlos III (ISCIII). Reference PI14/01911. 2015-2019.
Study of epigenetic modifications induced by cytomegalovirus as risk and prognostic markers. PI: Irene Gracia-Ahufinger. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI14/01225. 2015-2019.
Importance of the selection of stable mutants and persisters on colistin heteroresistance in Klebsiella pneumoniae. PI: Luis Martínez-Martínez. Funding agency: National Institute of Health Carlos III (ISCIII) Reference PI17-02241. 2018-2020.
Spanish National Survey on Pseudomonas aeruginosa Antimicrobial Resistance and Epidemiology: Detecting High-risk Clones to Optimize Antipseudomonal Treatments. PI: Antonio Oliver (Mallorca). Co-PI: Luis Martínez-Martínez. Funding agency: Merck, Sharp & Dhome. 2017-2018.
Precision diagnosis and treatment in Infectious Diseases and Cancer. Challenge: Analysis of microbial susceptibility and resistance to antibiotics (ASURANT). IPs Asurant: José Miguel Cisneros and Luis Martínez Martínez. Funding Agency: Ministry of Economy and Industry and Andalusian Health System. 2018-2022.
Study of the mechanisms of resistance to cetazidime-avibactam in isolates of Klebsiella pneumoniae producing KPC-3 cultured form patients under ceftazidime-avibactam therapy. Funding agency: Pfizer GEP, SLU. 2018-2019.
Epidemiological study to estimate the distribution of O serotypes among extraintestinal pathogenic Escherichia coli (ExPEC) from hospitalized patients of any age group with invasive disease by ExpEC ant to evaluate the definition of clinical case and risk factors. Funding Agency: Janssen-Cilag International NV. 2019-2020.
Recent Publications (2017-2019)
2017
Sánchez-Diener I, et al. Interplay among resistance profiles, high-risk clones and virulence in the Caenorhabditis elegans Pseudomonas aeruginosa infection model. Antimicrob Agents Chemother. 2017, 61: pii: AAC.01586-17.
Del Barrio-Tofiño E, et al. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrob Agents Chemother. 2017: 61. pii: e01589-17.
Alibi S, et al. Occurrence of Corynebacterium striatum as an emerging antibiotic-resistant nosocomial pathogen in a Tunisian hospital. Sci Rep. 2017 Aug 28;7:9704.
Lázaro-Díez M, et al. Human neutrophils phagocytose and kill Acinetobacter baumannii and A. pittii. Sci Rep. 2017 Jul 4;7:4571.
Machuca I, et al. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Antimicrob Agents Chemother 2017 Jul 25;61. pii: e00406-17.
Delgado-Valverde M et al. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. J Antimicrob Chemother 2017 May 1;72:1478-1487.
Gonzalez-Garcia FJ, et al. Fatal bilateral haemopneumothoraces following double-lung transplantation caused by pretransplant colonization by Scedosporium apiospermum. Eur J Cardiothorac Surg. 2017 Jun 1;51:1209.
Ruiz P, Causse M, Vaquero M, Gutierrez JB, Casal M. Evaluation of a new automated Abbott RealTime MTB RIF/INH assay for qualitative detection of rifampicin/isoniazid resistance in pulmonary and extra-pulmonary clinical samples of Mycobacterium tuberculosis. Infecti Drug Resist 2017, 10:463-467.
2018
Quiñonero A, del Molino ICP, de la Fuente CG, Sanjuan MC, Aguero J, Martinez-Martinez L. Phenotypic detection of clinical isolates of Haemophilus influenzae with altered penicillin-binding protein 3. Eur J Clin Microbiol Infect Dis 2018; 37:1475-1480.
Fernandez-Martinez M, del Castillo BR, Lecea-Cuello MJ, Rodriguez-Bano J, Pascual A, Martinez-Martinez L. Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum B-Lactamases Collected in Two Multicenter Studies in Spain. Microb Drug Resist 2018; 24:367-376.
Gutierrez-Aroca JB, Ruiz P, Vaquero M, Causse M, Casal M. Surveillance of Drug-Resistant Tuberculosis in Spain (2001-2015). Microb Drug Resist 2018; 24:839-843.
Gutierrez-Aroca JB, Ruiz-Martinez P, Rodriguez-Ruiz L, Casal-Roman M. Distribution of hepatitis C genotypes in the city of Cordoba. Rev Esp Quimioter 2018; 31:164-165.
Cano A, Gutierrez-Gutierrez B, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Causse M, Caston JJ, Guzman-Puche J, Torre-Gimenez J, Kindelan L, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J. Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management. Clin Infect Dis 2018: 66:1204-1210.
Amat T, Gutierrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 2018: 24:630-634.
Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen YC, Chakrabarti A, Chowdhary A, Chryssanthou E, Cordoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Florl C, Linares-Sicilia MJ, Martin-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM. Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values. Antimicrob Agents Chemother 2018: 62: e01916-17.
Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, astro C, Chen YC, Chen Y, Chryssanthou E, Dannaoui E, Garcia-Effron G, Gonzalez GM, Govender NP, Guinea J, Kidd S, Lackner M, Lass-Flörl C, Linares-Sicilia MJ, López-Soria L, Magobo R, Pelaez T, Quindós G, Rodriguez-Iglesia MA, Ruiz MA, Sánchez-Reus F, Sanguinetti M, Shields R, Szweda P, Tortorano A, Wengenack NL, Bramati S, Cavanna C, DeLuca C, Gelmi M, Grancini A, Lombardi G, Meletiadis J, Negri CE, Passera M, Peman J, Prigitano A, Sala E, Tejada M. Method-dependent epidemiological cutoff values (ECVs) for detection of triazole resistance in Candida and Aspergillus species for the SYO colorimetric broth and Etest agar diffusion methods. Antimicrob Agents Chemother 2019, 63: pii: AAC.01651-18.
Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menendez O, Ayats J, Castro C, Garcia-Rodriguez J, Goterris-Bonet L, Ibanez-Martinez E, Linares-Sicilia MJ, Martin-Gomez MT, Martin-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Anza DV, Vinuelas J, Zapico MS, Cuenca-Estrella M. Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study). Antimicrob Agents Chemother 2018: 62: e00358-18.
Hamzaoui Z, Ocampo-Sosa A, Martinez MF, Landolsi S, Ferjani S, Maamar E, Saidani M, Slim A, Martinez-Martinez L, Boutiba-Ben Boubaker I. Role of association of OmpK35 and OmpK36 alteration and bla(ESBL) and/or bla(AmpC) genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2018, 52:898-905.
Garcia-Castillo M, Garcia-Fernandez S, Gomez-Gil R, Pitart C, Oviano M, Gracia-Ahufinger I, Diaz-Reganon J, Tato M, Canton R. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. Int J Antimicrob Agents 2018, 51:511-515.
Lopez M, Rueda A, Florido JP, Blasco L, Fernandez-Garcia L, Trastoy R, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Pascual A, Bou G, Tomas M. Evolution of the Quorum network and the mobilome (plasmids and bacteriophages) in clinical strains of Acinetobacter baumannii during a decade. Sci Rep 2018, 8:2523.
Zboromyrska Y, Bosch J, Aramburu J, Cuadros J, Garcia-Riestra C, Guzman-Puche J, Martos CL, Loza E, Munoz-Algarra M, de Alegria CR, Sanchez-Hellin V, Vila J. A multicentre study investigating parameters which influence direct bacterial identification from urine. Plos One. 2018: 13: Núm artículo e0207822.
Fernandez-Garcia L, Ambroa A, Blasco L, Bleriot I, Lopez M, Alvarez-Marin R, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Rodriguez-Bano J, Gamacho-Montero J, Cisneros JM, Pascual A, Pachon J, Bou G, Smani Y, Tomas M. Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii. Front Microbiol 2018; 9: 3105
Cerezales M, Ocampo-Sosa AA, Montes LA, Rios CD, Bustamante Z, Santos J, Martinez-Martinez L, Higgins PG, Gallego L. High Prevalence of Extensively Drug-resistant Acinetobacter baumannii at a Children Hospital in Bolivia. Ped Infect Dis J 2018, 37:1118-1123.
Aguado JM, Silva JT, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C, Martinez-Martinez L, Vidal E, Almenar L, Almirante B, Canton R, Carratala J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernandez J, Farinas MC, Gavalda J, Goyanes MJ, Gutierrez-Gutierrez B, Hernandez D, Len O, Lopez-Andujar R, Lopez-Medrano F, Martin-Davila P, Montejo M, Moreno A, Oliver A, Pascual A, Perez-Nadales E, Roman-Broto A, San-Juan R, Seron D, Sole-Jover A, Valerio M, Munoz P, Torre-Cisneros J. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev 2018, 32:36-57.
Cercenado E, Canton R, Ramirez MG, Mansilla CA, Ahufinger IG, Ramirez MG, Alarcon JM. Procedures in Clinical Microbiology (number 15.(a), 2nd edition 2018). Enf Infec Microbiol Clin 2018, 36:603-603.
Rodriguez-Lozano J, de Malet A, Cano ME, de la Rubia L, Wallmann R, Martinez-Martinez L, Calvo J. Antimicrobial susceptibility of microorganisms that cause urinary tract infections in pediatric patients. Enf Infec Microbiol Clin 2018, 36:417-422.
2019
Ruiz P, Causse M, Vaquero M, Casal M. In Vitro Activity of Tedizolid against ycobacterium tuberculosis. Antimicrob Agents Chemother. 2019, 63. pii:e01939-18. doi: 10.1128/AAC.01939-18.
Guzmán-Puche J, Gracia-Ahufinger I, Causse M, Tejero-García R, Rodríguez-López FC, Casal-Román M. Combination of Coral UTI Screen(TM) system, gram-stain and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for diagnosis of urinary tract infections directly from urine samples. J Chemother. 2019, 2:74-80.
Kieffer N, Guzmán-Puche J, Poirel L, Kang HJ, Jeon CO, Nordmann P. ZHO-1, an intrinsic MBL from the environmental Gram-negative species Zhongshania aliphaticivorans. J Antimicrob Chemother. 2019, 74:1568-1571.
Castro C, Galán-Sanchez F, Linares MJ, Tejero R, Ruiz M, Serrano ML, Rodríguez-Iglesias M, Martín-Mazuelos E; FUNGAE-IFI Study Group. A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns. Med Mycol. 2019, 57:412-420.
López-Camacho E, Paño-Pardo JR, Sotillo A, Elías-López C, Martínez-Martínez L, Gómez-Gil R, Mingorance J. Meropenem heteroresistance in clinical isolates of OXA-48-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2019, 93:162-166.
Haeili M, Kafshdouz M, Pishnian Z, Feizabadi MM, Martínez-Martínez L. Comparison of susceptibility testing methods for determining the activity of colistin against Gram-negative bacilli of clinical origin. J Med Microbiol 2019, 68:60-66.
Ishikawa M, García-Mateo N, Čusak A, López-Hernández I, Fernández-Martínez M, Müller M, Rüttiger L, Singer W, Löwenheim H, Kosec G, Fujs Š, Martínez-Martínez L, Schimmang T, Petković H, Knipper M, Durán-Alonso MB. Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Sci Rep. 2019, 9:2410.
[Ruiz]de Alegría Puig C[R], Torres MF, Marfil-Pérez E, Ferández MIR, Del Río MC,Balbín JA, Martínez-Martínez L. Comparison between Vitek MS, Bruker Biotyper,Vitek2, and API20E for differentiation of species of the genus Raoultella. Eur J Clin Microbiol Infect Dis. 2019 , 38:467-470.
Cirit OS, Fernández-Martínez M, Yayla B, Martínez-Martínez L. Aminoglycoside resistance determinants in multiresistant Escherichia coli and Klebsiella pneumoniae clinical isolates from Turkish and Syrian patients. Acta Microbiol Immunol Hung. 2019 Feb 26:1-9.
Pérez-Vazquez M, Oteo-Iglesias J, Sola-Campoy PJ, Carrizo-Manzoni H, Bautista V, Lara N, Aracil B, Alhambra A, Martínez-Martínez L, Campos J; Spanish Antibiotic Resistance Surveillance Program collaborating Group. Characterization of carbapenemase-producing Klebsiella oxytoca in Spain, 2016-2017. Antimicrob Agents Chemother 2019 e02529-18.
Palacios-Baena ZR, Delgado-Valverde M, Valiente Méndez A, Almirante B, Gómez-Zorrilla S, Borrell N, Corzo JE, Gurguí M, de la Calle C, García-Álvarez L,Ramos L, Gozalo M, Morosini MI, Molina J, Causse M, Pascual Á, Rodríguez-Baño J; REIPI/GEIRAS-SEIMC BACTERIEMIA-MIC group. Impact of de-escalation on prognosis of patients with bacteraemia due to Enterobacteriaceae: a post-hoc analysis from a multicenter prospective cohort. Clin Infect Dis. 2019, 69: 956-962.
Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, López-Causapé C, Sánchez-Diener I, Cabot G, Bou G, Martínez-Martínez L, Oliver A;GEMARA-SEIMC/REIPI Pseudomonas study Group . Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. J Antimicrob Chemother. 2019 Apr 15. pii: dkz147.
Ramos-Vivas J, Chapartegui-González I, Fernández-Martínez M, González-Rico C, Fortún J, Escudero R, Marco F, Linares L, Montejo M, Aranzamendi M, Muñoz P, Valerio M, Aguado JM, Resino E, Ahufinger IG, Vega AP, Martínez L, Fariñas MC; ENTHERE Study Group, the Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. Sci Rep. 2019, 9:8928.
Rodriguez-Gómez J, Pérez-Nadales E, Gutiérrez-Gutiérrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Castón JJ, Robles JC, la Fuente C, Rodríguez-López F, Rodriguez-Baño J, Torre-Cisneros J; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain. Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: the impact of inappropriate empirical treatment. J Infect 2019, 79: 245-252.
Camprubí-Font C, Ruiz del Castillo B, Barrabés S, Martínez-Martínez L, Martinez-Medina M. Amino acid substitutions and differential gene expression of outer membrane proteins in adherent-invasive Escherichia coli. Front Microbiol 2019, 10: 1707.
Del Barrio-Tofiño E, Sánchez-Diener I, Zamorano L, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. J Antimicrob Chemother 2019, 74: 3217–3220.
Martínez-Martínez L. Carbapenemases: The never-ending story. Enferm. Infecc. Microbiol. Clin. 2019, 37:73-75.
Paez-Vega A, Cantisan S, Vaquero JM, Vidal E, Luque-Pineda A, Lobo-Acosta MÁ, Pérez AB, Alonso-Moralejo R, Iturbe D, Monforte V, Otero-Gonzalez I, Pastor A, Ussetti P, Torre-Cisneros J. Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial. BMJ Open. 2019 Aug 15;9(8):e030648. doi: 10.1136/bmjopen-2019-030648.
Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One. 2019 Aug 30;14(8):e0221231. doi: 10.1371/journal.pone.0221231.
Álvarez-Marín R, Navarro-Amuedo D, Gasch-Blasi O, Rodríguez-Martínez JM, Calvo-Montes J, Lara-Contreras R, Lepe-Jiménez JA, Tubau-Quintano F, Cano-García ME, Rodríguez-López F, Rodríguez-Baño J, Pujol-Rojo M, Torre-Cisneros J, Martínez-Martínez L, Pascual-Hernández Á, Jiménez-Mejías ME. A prospective, multicenter case control study of risk factors for acquisition and mortality in Enterobacter species bacteremia. J Infect. 2020 Feb;80(2):174-181. doi: 10.1016/j.jinf.2019.09.017.
Lucia Blasco, Anton Ambroa , Maria Lopez , Laura Fernandez-Garcia , Ines Bleriot , Rocio Trastoy , Jose Ramos-Vivas , Tom Coenye , Felipe Fernandez-Cuenca , Jordi Vila, Luis Martinez-Martinez , Jesus Rodriguez-Baño, Alvaro Pascual , Jose Miguel Cisneros, Jeronimo Pachon, German Bou and Maria Tomas. Combined Use of the Ab105-2ϕ∆CI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. Microorganisms 2019, 7, 556; doi:10.3390/microorganisms7110556
Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Téllez F, Bernal E, Rincón P, Von Wichman MA, Fuentes A, Vera F, Rivero-Juárez A, Jiménez M, Vandamme AM, García F. Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. J Hepatol. 2019 Dec;71(6):1270-1272.
